Story
Johnson & Johnson Shares Rise on Report of $20 Billion Orthopedics Unit Sale Talks
Summary
Shares of the healthcare giant gained after reports that Apollo Global Management is in discussions to acquire its DePuy Synthes orthopedics division for nearly $20 billion, accelerating the unit's planned separation.
Johnson & Johnson (NYSE: JNJ) shares climbed in pre-market trading, outperforming a declining broader market, following reports that private equity firm Apollo Global Management is in talks to acquire its orthopedics division for nearly $20 billion.
Details of the Potential Divestiture
Shares of J&J rose 1.4% in pre-open trading Monday after reports surfaced late Friday that Apollo is in active discussions to purchase the DePuy Synthes orthopedics business. The news, initially reported by Bloomberg and subsequently confirmed by The Wall Street Journal, suggests a significant acceleration of J&J's plans to separate the unit.
Investors appear to view a direct sale as a more efficient and value-accretive path than the standalone spinoff J&J had announced in October 2025. A deal would allow the company to quickly unlock capital and streamline its focus on higher-growth segments.
Strategic Rationale and Market Context
A sale of DePuy Synthes would align with J&J's strategy to concentrate on its higher-margin Innovative Medicine and core MedTech businesses. At the recent Wells Fargo Healthcare Conference, MedTech chairman Tim Schmid reiterated the company's commitment to finding the path for the separation—whether a sale or a public spin—that creates the most shareholder value.
AdThe stock's advance is particularly notable given the negative market sentiment on Monday morning. J&J's gain came as S&P 500 futures slipped 0.7% and the Dow Jones Industrial Average fell 0.4%, underscoring that the move was driven by company-specific news rather than a broader market tailwind.
Supporting Catalysts
Beyond the potential deal, other factors are supporting investor sentiment. J&J management is presenting today at the Morgan Stanley 24th Annual Global Healthcare Conference, providing direct engagement with institutional investors.
Furthermore, the company recently published positive Phase 3 PAPILLON data for its lung cancer treatment, Rybrevant. The study highlighted the strength of J&J's oncology pipeline, showing a median overall survival of 34.3 months for patients treated with Rybrevant versus 27.9 months for chemotherapy alone.
Read next
More on Stocks
Nucor Stock Slides After Q3 Earnings Guidance Misses Analyst Forecasts
Nucor Corporation (NUE) shares fell after the company projected third-quarter earnings of $5.55 to $5.65 per share, below the Wall Street consensus of $5.99, citing the absence of significant one-time gains from the prior quarter.
Disney Asks Court to Halt FCC License Review, Alleges Political Pressure From Trump
The Walt Disney Company has filed a legal challenge to stop the Federal Communications Commission from conducting an early review of its ABC station licenses, claiming the regulator is acting on President Trump's directives.
Starbucks Settles Florida Lawsuit Over Diversity Policies for $1 Million
The coffee giant has agreed to settle a lawsuit with Florida's attorney general, pledging to avoid race- or sex-based quotas in its employment practices and pay $1 million to cover the state's litigation costs.
Latin American Stocks Rally as Dollar Slides After Fed Rate Hike
Equities and currencies across Latin America gained as a pullback in the U.S. dollar following the Federal Reserve's latest interest rate increase boosted commodity-linked assets and improved investor sentiment toward emerging markets.